| SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition A Nelde, T Bilich, JS Heitmann, Y Maringer, HR Salih, M Roerden, ... Nature immunology 22 (1), 74-85, 2021 | 590 | 2021 |
| HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL) DJ Kowalewski, H Schuster, L Backert, C Berlin, S Kahn, L Kanz, ... Proceedings of the National Academy of Sciences 112 (2), E166-E175, 2015 | 192 | 2015 |
| A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity JS Heitmann, T Bilich, C Tandler, A Nelde, Y Maringer, M Marconato, ... Nature 601 (7894), 617-622, 2022 | 179 | 2022 |
| The immunopeptidomic landscape of ovarian carcinomas H Schuster, JK Peper, HC Bösmüller, K Röhle, L Backert, T Bilich, B Ney, ... Proceedings of the National Academy of Sciences 114 (46), E9942-E9951, 2017 | 170 | 2017 |
| Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy C Berlin, DJ Kowalewski, H Schuster, N Mirza, S Walz, M Handel, ... Leukemia 29 (3), 647-659, 2015 | 156 | 2015 |
| T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals T Bilich, A Nelde, JS Heitmann, Y Maringer, M Roerden, J Bauer, J Rieth, ... Science translational medicine 13 (590), eabf7517, 2021 | 153 | 2021 |
| HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy A Marcu, L Bichmann, L Kuchenbecker, DJ Kowalewski, ... Journal for immunotherapy of cancer 9 (4), 2021 | 153 | 2021 |
| The peptide vaccine of the future A Nelde, HG Rammensee, JS Walz Molecular & Cellular Proteomics 20, 2021 | 125 | 2021 |
| The antigenic landscape of multiple myeloma: mass spectrometry (re) defines targets for T-cell–based immunotherapy S Walz, JS Stickel, DJ Kowalewski, H Schuster, K Weisel, L Backert, ... Blood, The Journal of the American Society of Hematology 126 (10), 1203-1213, 2015 | 118 | 2015 |
| Human NACHT, LRR, and PYD domain–containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase X Liu, T Pichulik, OO Wolz, TM Dang, A Stutz, C Dillen, MD Garcia, ... Journal of Allergy and Clinical Immunology 140 (4), 1054-1067. e10, 2017 | 117 | 2017 |
| Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells S Maurer, KN Kropp, G Klein, A Steinle, SP Haen, JS Walz, C Hinterleitner, ... Oncoimmunology 7 (2), e1364827, 2018 | 87 | 2018 |
| Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer C Hinterleitner, J Strähle, E Malenke, M Hinterleitner, M Henning, ... Nature communications 12 (1), 7005, 2021 | 79 | 2021 |
| Magnetic bead-based immunoassay allows rapid, inexpensive, and quantitative detection of human SARS-CoV-2 antibodies LF Huergo, KA Selim, MS Conzentino, ECM Gerhardt, ARS Santos, ... ACS sensors 6 (3), 703-708, 2021 | 70 | 2021 |
| Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity M Becker, M Strengert, D Junker, PD Kaiser, T Kerrinnes, B Traenkle, ... Nature communications 12 (1), 1152, 2021 | 69 | 2021 |
| The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy T Bilich, A Nelde, L Bichmann, M Roerden, HR Salih, DJ Kowalewski, ... Blood, The Journal of the American Society of Hematology 133 (6), 550-565, 2019 | 68 | 2019 |
| Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD S Wabitsch, JD McCallen, O Kamenyeva, B Ruf, JC McVey, J Kabat, ... Journal of hepatology 77 (3), 748-760, 2022 | 65 | 2022 |
| HLA ligand profiles of primary renal cell carcinoma maintained in metastases JS Stickel, AO Weinzierl, N Hillen, O Drews, MM Schuler, J Hennenlotter, ... Cancer immunology, immunotherapy 58, 1407-1417, 2009 | 65 | 2009 |
| A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer HG Rammensee, KH Wiesmüller, PA Chandran, H Zelba, E Rusch, ... Journal for immunotherapy of cancer 7, 1-18, 2019 | 64 | 2019 |
| Steatohepatitis impairs T-cell–directed immunotherapies against liver tumors in mice B Heinrich, ZJ Brown, LP Diggs, M Vormehr, C Ma, V Subramanyam, ... Gastroenterology 160 (1), 331-345. e6, 2021 | 55 | 2021 |
| HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell … A Nelde, DJ Kowalewski, L Backert, H Schuster, JO Werner, R Klein, ... Oncoimmunology 7 (4), e1316438, 2018 | 48 | 2018 |
Hans-Georg RammenseeProf. ImmunologyVerified email at uni-tuebingen.de
